Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Biomarkers - From Research To Commercialization


Coumestan Derivatives ameliorates Colitis via attenuating Colonic Regulating Pro-Inflammatory Cytokines Production in Rats

T Prakash, Professor, Acharya & BM Reddy College of Pharmacy

The present study was designed to evaluate the effect of Coumestan in indomethacin-induced enterocolitis in rats. Wistar rats was divided into three groups containing eight animals in each group. Group I served as a normal control. Group II & Group III receive 7.5 mg/kg Indomethacin, subcutaneously on two consecutive days. Group III were received Coumestan dose of 100 mg/kg, p.o., for 14 days after the induction with indomethacin. The protective effect was assessed on the basis of intestinal parameters of Disease activity index, Colitis Score, Myeloperoxidase activity in colon. The severity of inflammation biomarkers was quantified by ELISA in the rat colon. Further, activity was ascertained by histopathological. Proinflammatory functions IL-1a, IL-1ß, IL-2, TNF, INF-?, STAT3 and CCL-5 are play a central role in the modulation of the intestinal immune system. Coumestan showed significantly decreased Disease activity index, Colitis score, Myeoloperoxidase activity. Expression of IL-1alpha, IL-1beta, IL-2, IL-6, TNF-a, INF-?, STAT3, and CCL-5 was increased in indomethacin induced groups. Indomethacin induced up-regulation of colonic IL-1alpha, IL-1beta, IL-2, IL-6, TNF-a, INF-?, STAT3, and CCL-5 were significantly (p<0.001& p<0.001) suppressed in animals given with Coumestan Histological reports also revealed that treated groups have comparatively less damage than that of the induced groups. 

Add to Calendar ▼2018-05-24 00:00:002018-05-25 00:00:00Europe/LondonBiomarkers - From Research To CommercializationBiomarkers - From Research To Commercialization in